Product Description
Esomeprazole is used to treat conditions where there is too much acid in the stomach. It is used to treat duodenal and gastric ulcers, erosive esophagitis, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome, a condition wherein the stomach produces too much acid. (Sourced from: https://www.mayoclinic.org/drugs-supplements/esomeprazole-oral-route/description/drg-20074322)
Mechanisms of Action: CYP2C19 Inhibitor,Proton Pump Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Acute Pain | Pain Unspecified | Arthritis, Juvenile | Arthritis, Rheumatoid | Spondylitis, Ankylosing | Spondylitis | Arthritis | Osteoarthritis
Known Adverse Events: Gastritis | Diarrhea
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Brazil, Canada, China, Germany, Greece, Italy, Japan, Lithuania, Portugal, Spain, United States
Active Clinical Trial Count: 23
Highest Development Phases
Phase 3: Asthma|Chronic Obstructive Pulmonary Disease|Duodenal Ulcer|Esophagitis|Esophagitis, Peptic|Gastroesophageal Reflux|Generalized anxiety disorder|Helicobacter Infections|Injuries/wounds Unspecified|Liver Cirrhosis|Peptic Ulcer|Stomach Ulcer
Phase 1: Bile Reflux|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Healthy Volunteers|Intestinal Diseases|Malnutrition|Medullary Carcinoma|Non-Small-Cell Lung Cancer|Sarcoma|Soft Tissue Cancer|Squamous Cell Carcinoma|Thyroid Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| D9612C09998 | P3 |
Unknown Status |
Esophagitis |
2026-08-17 |
|
| SOLACE | P3 |
Active, not recruiting |
Esophagitis |
2026-05-02 |
|
| ESPIRE | P3 |
Recruiting |
Asthma|Chronic Obstructive Pulmonary Disease |
2025-03-30 |
95% |
| STOPPIT | P3 |
Active, not recruiting |
Liver Cirrhosis |
2025-03-08 |